Dogwood Therapeutics, Inc.
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a fixed dose combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-… Read more
Dogwood Therapeutics, Inc. (DWTX) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.042x
Based on the latest financial reports, Dogwood Therapeutics, Inc. (DWTX) has a cash flow conversion efficiency ratio of -0.042x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.27 Million) by net assets ($77.39 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Dogwood Therapeutics, Inc. - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Dogwood Therapeutics, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Dogwood Therapeutics, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Dogwood Therapeutics, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
GLACIER LAKE RES
F:KDM
|
N/A |
|
Dantax
CO:DANT
|
-0.004x |
|
Mask Investments Limited
NSE:MASKINVEST
|
-0.002x |
|
First Au Limited
PINK:FRSAF
|
-0.107x |
|
SPEQTA AB
F:23WA
|
N/A |
|
Strategic Partners A/S
F:1TB0
|
N/A |
|
Lexston Life Sciences Corp
OTCQB:LEXTF
|
-0.794x |
|
RIGHTBRIDGE VENTURES GRP
F:K0B0
|
N/A |
Annual Cash Flow Conversion Efficiency for Dogwood Therapeutics, Inc. (2018–2024)
The table below shows the annual cash flow conversion efficiency of Dogwood Therapeutics, Inc. from 2018 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $64.28 Million | $-8.79 Million | -0.137x | +89.31% |
| 2023-12-31 | $3.81 Million | $-4.87 Million | -1.279x | +18.26% |
| 2022-12-31 | $7.33 Million | $-11.47 Million | -1.565x | -44.67% |
| 2021-12-31 | $14.50 Million | $-15.69 Million | -1.082x | -731.66% |
| 2020-12-31 | $29.94 Million | $-3.90 Million | -0.130x | -130.73% |
| 2019-12-31 | $-4.94 Million | $-2.09 Million | 0.423x | -55.39% |
| 2018-12-31 | $-1.26 Million | $-1.20 Million | 0.949x | -- |